European experience of biosimilars a sign of what's to come in USA, says Samsung Bioepis CEO

For biosimilar companies in Europe, data showing the savings that their products are delivering are becoming just as important as findings on biosimilarity.

The latter is considered a given now, with patients and physicians across the continent now widely convinced of the similar safety and efficacy of biosimilars, even if companies continue to present real-world evidence confirming their impact over a long period at events like EULAR, the recent rheumatology congress.

This meeting allowed Samsung Bioepis and Biogen (Nasdaq: BIIB) to present data not just on the safety and efficacy of their anti-TNF biosimilars and high adherence rates of patients, but also to provide evidence on savings delivered to European healthcare systems.